Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MTX 325

Next Previous
Drug Profile

MTX 325

Alternative Names: MTX-325

Latest Information Update: 02 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie; MISSION Therapeutics
  • Developer MISSION Therapeutics
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Usp30 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Parkinson's disease
  • Preclinical Pelizaeus-Merzbacher disease

Most Recent Events

  • 27 Aug 2026 Mission Therapeutics and NeuraLight enters into a partnership to deploy NeuraLight's brain function biomarker assessments across multinational trial of MTX 325 in Parkinson's disease
  • 17 Jul 2026 MISSION Therapeutics has patent protection for MTX 325
  • 05 Dec 2023 MISSION Therapeutics plans a first-in-human phase I trial for Parkinson's disease in United Kingdom, in the first quarter of 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top